Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Thalidomide, celecoxib, and fenofibrate may stop the growth of cancer
cells by blocking blood flow to the cancer. Celecoxib also may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy
together with thalidomide, celecoxib, and fenofibrate may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving etoposide and cyclophosphamide
together with thalidomide, celecoxib, and fenofibrate works in treating young patients with
relapsed or progressive cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Boston Children's Hospital Boston Children’s Hospital National Cancer Institute (NCI)